PubRank

Norio Akuta

Author PubWeight™ 150.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013 5.03
2 Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013 2.36
3 HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2010 1.85
4 Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009 1.83
5 Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008 1.76
6 Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2008 1.67
7 Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004 1.66
8 Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol 2006 1.65
9 Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008 1.59
10 Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012 1.53
11 Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004 1.46
12 Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003 1.46
13 Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003 1.45
14 Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002 1.43
15 Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 2004 1.42
16 Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004 1.41
17 Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012 1.35
18 IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011 1.33
19 Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005 1.26
20 Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2011 1.21
21 Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011 1.12
22 Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002 1.06
23 Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007 1.00
24 Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol 2013 1.00
25 Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology 2003 1.00
26 Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 2002 0.99
27 Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 2009 0.99
28 High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009 0.99
29 Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005 0.98
30 Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007 0.98
31 Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009 0.97
32 Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006 0.97
33 YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 2004 0.97
34 Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 2008 0.96
35 Necessities of interferon therapy in elderly patients with chronic hepatitis C. Am J Med 2009 0.96
36 Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006 0.96
37 An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009 0.95
38 Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004 0.95
39 A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 2006 0.95
40 Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007 0.94
41 Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002 0.94
42 Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011 0.93
43 Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 2010 0.93
44 Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005 0.92
45 Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up. J Med Virol 2005 0.91
46 Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol 2008 0.91
47 Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol 2012 0.91
48 Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2009 0.91
49 Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006 0.91
50 Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection. J Gastroenterol 2004 0.90
51 Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma. Oncology 2002 0.90
52 Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 2008 0.89
53 Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007 0.88
54 Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 2012 0.87
55 Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005 0.87
56 Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter. Hepatol Res 2005 0.87
57 Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003 0.87
58 Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. Hepatol Res 2007 0.86
59 Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009 0.86
60 Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2007 0.86
61 Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2011 0.86
62 Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol 2012 0.86
63 Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007 0.86
64 Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2011 0.86
65 Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 2012 0.86
66 Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int 2008 0.86
67 Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology 2003 0.85
68 Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol 2011 0.85
69 Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology 2012 0.85
70 Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res 2009 0.85
71 Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010 0.85
72 HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010 0.85
73 Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2012 0.84
74 A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol Res 2013 0.84
75 Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 2013 0.84
76 Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model. Liver Int 2011 0.84
77 Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2008 0.84
78 Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology 2004 0.83
79 Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. Intervirology 2003 0.83
80 Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. Hepatol Res 2003 0.83
81 Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006 0.83
82 Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 2011 0.83
83 Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009 0.83
84 Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J Gastroenterol Hepatol 2004 0.83
85 Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 2008 0.83
86 A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013 0.83
87 Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL. Hepatol Res 2012 0.82
88 Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002 0.82
89 Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002 0.82
90 Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology 2005 0.82
91 Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study. Hepatol Res 2014 0.82
92 Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 2010 0.82
93 Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology 2004 0.81
94 Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2004 0.81
95 Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol 2013 0.81
96 Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 2007 0.81
97 Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 2011 0.81
98 Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 2010 0.81
99 Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2004 0.81
100 A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern Med 2003 0.81
101 Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010 0.81
102 Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol 2006 0.80
103 Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. Intervirology 2006 0.80
104 Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res 2013 0.80
105 Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. Hepatol Res 2014 0.80
106 Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. Hepatol Res 2012 0.80
107 Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology 2007 0.80
108 Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 2012 0.80
109 Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Intervirology 2004 0.80
110 Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma. Oncology 2016 0.80
111 Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol 2013 0.80
112 Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011 0.79
113 Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007 0.79
114 Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer. J Gastroenterol Hepatol 2006 0.79
115 Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006 0.79
116 Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis. J Gastroenterol 2004 0.79
117 Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol 2005 0.79
118 Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007 0.79
119 The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011 0.79
120 Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005 0.79
121 Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010 0.78
122 Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model. Oncology 2014 0.78
123 HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy. Liver Int 2014 0.78
124 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Intern Med 2010 0.78
125 Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med 2008 0.78
126 Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. Gut Liver 2013 0.78
127 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern Med 2011 0.78
128 Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol 2008 0.78
129 Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intervirology 2008 0.78
130 Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006 0.78
131 Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 2009 0.78
132 Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res 2007 0.78
133 New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res 2010 0.78
134 A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. J Virol Methods 2006 0.78
135 The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load. Intern Med 2008 0.78
136 Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 2006 0.78
137 Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007 0.77
138 Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 2003 0.77
139 Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. J Gastroenterol Hepatol 2005 0.77
140 Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients. Hepatol Res 2002 0.77
141 Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy. J Gastroenterol 2004 0.77
142 Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003 0.77
143 Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 2008 0.77
144 Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 2009 0.77
145 Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. Hepatol Res 2012 0.77
146 The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. Intern Med 2009 0.77
147 Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma. Oncology 2015 0.77
148 Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses. Hepatol Res 2008 0.77
149 Prolonged hepatitis after acute infection with genotype H hepatitis B virus. Intern Med 2007 0.77
150 Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease. Hepatol Res 2013 0.76
151 Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003 0.76
152 Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Intern Med 2009 0.76
153 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Intern Med 2010 0.76
154 What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study. Gut Liver 2013 0.76
155 [Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure]. Nihon Shokakibyo Gakkai Zasshi 2011 0.76
156 Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol 2006 0.76
157 The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load. Intern Med 2008 0.76
158 Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol 2013 0.76
159 Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 2008 0.76
160 Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res 2007 0.76
161 Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis. Dig Dis Sci 2010 0.76
162 Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome. Liver Int 2007 0.76
163 Usefulness of the serum KL-6 assay in patients with hepatitis C virus. Intervirology 2005 0.76
164 Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 2009 0.76
165 High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. J Gastroenterol 2004 0.75
166 New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int 2015 0.75
167 Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤ 6.4% in Japan. Intern Med 2015 0.75
168 New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle. Liver Int 2007 0.75
169 [Natural course and treatment guideline for chronic HBV infection]. Nihon Rinsho 2015 0.75
170 Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. Oncology 2017 0.75
171 Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. Hepatol Res 2007 0.75
172 Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma. Hepatol Res 2013 0.75
173 Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. Scand J Gastroenterol 2009 0.75
174 Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B. Intervirology 2006 0.75
175 [Outline of HCV treatment]. Nihon Rinsho 2015 0.75
176 Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology 2004 0.75
177 The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load. Intervirology 2008 0.75
178 Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Intern Med 2007 0.75
179 HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B. J Med Virol 2003 0.75
180 Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation. J Gastroenterol 2004 0.75
181 Lipiodol and dye at the site of ablation decreases during RFA. Intervirology 2009 0.75
182 Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. J Gastroenterol 2004 0.75
183 Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. J Med Virol 2007 0.75